IN2012DN00534A - - Google Patents

Info

Publication number
IN2012DN00534A
IN2012DN00534A IN534DEN2012A IN2012DN00534A IN 2012DN00534 A IN2012DN00534 A IN 2012DN00534A IN 534DEN2012 A IN534DEN2012 A IN 534DEN2012A IN 2012DN00534 A IN2012DN00534 A IN 2012DN00534A
Authority
IN
India
Prior art keywords
ozone
conditions
dose
disclosed
methods
Prior art date
Application number
Inventor
S LATINO Joseph
A KEYSER Steven
Original Assignee
Acquisci Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acquisci Inc filed Critical Acquisci Inc
Priority claimed from US12/819,871 external-priority patent/US20100318014A1/en
Priority claimed from US12/819,875 external-priority patent/US20100316730A1/en
Priority claimed from US12/819,886 external-priority patent/US20100316727A1/en
Publication of IN2012DN00534A publication Critical patent/IN2012DN00534A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treating mammalian subjects suffering from  or believed to be suffering from  acute ischemic brain stroke  cardiovascular disease  inflammatory disease or any of the conditions or symptoms related to those diseases  are disclosed in which a biological fluid withdrawn from the subject is processed through an ozone delivery system to deliver a measured amount of ozone to the biological fluid to produce a treated fluid that has a quantifiable absorbed-dose of ozone which  upon re-introduction of the treated fluid containing the quantifiable absorbed-dose of ozone to the subject  effectively treats any number of described disease conditions and symptoms. Methods for manufacturing medicaments for treatment of acute ischemic brain stroke  cardiovascular disease  inflammatory disease or any of the conditions or symptoms related to those diseases  are also disclosed.
IN534DEN2012 2009-06-19 2010-06-21 IN2012DN00534A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26908709P 2009-06-19 2009-06-19
US26909109P 2009-06-19 2009-06-19
US26909009P 2009-06-19 2009-06-19
US12/819,871 US20100318014A1 (en) 2003-07-31 2010-06-21 Treatment of acute ischemic brain stroke with ozone
PCT/US2010/001785 WO2010147677A2 (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
US12/819,875 US20100316730A1 (en) 2003-07-31 2010-06-21 Treatment of cardiovascular diseases with ozone
US12/819,886 US20100316727A1 (en) 2003-07-31 2010-06-21 Treatment of inflammatory disorders with ozone

Publications (1)

Publication Number Publication Date
IN2012DN00534A true IN2012DN00534A (en) 2015-06-05

Family

ID=43356980

Family Applications (1)

Application Number Title Priority Date Filing Date
IN534DEN2012 IN2012DN00534A (en) 2009-06-19 2010-06-21

Country Status (5)

Country Link
EP (1) EP2442819A4 (en)
AU (1) AU2010260467A1 (en)
CA (1) CA2765479A1 (en)
IN (1) IN2012DN00534A (en)
WO (1) WO2010147677A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018035504A1 (en) 2016-08-19 2018-02-22 Lane Ronald Howard Gas treatment delivery systems and methods
EP3500277A4 (en) * 2016-08-19 2020-04-15 Immunores-Therapeutics, LLC Gas treatment delivery systems and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
CA2308105A1 (en) * 2000-05-11 2001-11-11 Vasogen Ireland Limited Treatment of il-10 deficiencies
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
US7736494B2 (en) * 2003-07-31 2010-06-15 Acquisci, Inc. Ozone delivery system including a variable pitch gas-fluid contact device
TR200600945T1 (en) * 2003-09-05 2006-10-26 The Scripps Research Institute Therapeutic methods.
JP2005348774A (en) * 2004-06-08 2005-12-22 Masako Negishi Treatment method for disease of animal and treatment apparatus for the same
US20080138432A1 (en) * 2004-07-20 2008-06-12 Vasogen Ireland Limited Acute Inflammatory Condition Treatment
US20060210644A1 (en) * 2004-12-16 2006-09-21 Bruce Levin Materials, methods, and devices for treatment of arthropathies and spondylopathies
WO2007115398A1 (en) * 2006-04-10 2007-10-18 Vasogen Ireland Limited Treatment of elevated c-reactive protein levels
EP1932524A1 (en) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmaceutical preparations for treating inflammatory diseases

Also Published As

Publication number Publication date
CA2765479A1 (en) 2010-12-23
WO2010147677A3 (en) 2011-05-12
EP2442819A4 (en) 2013-01-02
EP2442819A2 (en) 2012-04-25
WO2010147677A2 (en) 2010-12-23
AU2010260467A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX2019002669A (en) Methods of treating behavioral symptoms of neurological and mental disorders.
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
CR20110128A (en) METHODS, SYSTEMS AND PRODUCTS TO PREACH THE RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT AND TREAT A PATIENT IN ACCORDANCE WITH THE PREDICTED RESPONSE
MX2011007397A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients.
IL222251A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
MX2013000674A (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
WO2015118537A3 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
MX2011011290A (en) Ex-vivo treatment of immunological disorders with pkc-theta inhibitors.
GB2477256A (en) Medicament and method of diagnosis
EP3818991A3 (en) Compositions and methods for treating diseases
FR20C1026I1 (en) CICLESONIDE FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT IN HORSES
FR2953395B1 (en) ORTHOPEDIC SOLE COMPRISING CORRECTION MEANS FOR THE TREATMENT OF METATARSALGIA AND PLANT CUTANEOUS DISEASES
BR112012026224A2 (en) methods for treating alzheimer's disease and for evaluating the effectiveness of a
HK1152649A1 (en) Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
IN2012DN00534A (en)
JP2014526564A5 (en)
MX2022010890A (en) Treatment and diagnosis of inflammatory disorders.
UA109359C2 (en) TREATMENT OF SKIN DISEASES AND STATES
BR112013025197A2 (en) methods for treating alzheimer's disease and for evaluating the effectiveness of therapy to treat alzheimer's disease
Khemthong et al. Effect of musical training on reaction time: A randomized control trial in Thai elderly individuals.
FR2931075B1 (en) FENUGREC EXTRACT FOR THE TREATMENT OF HUMAN AND ANIMAL DISEASES INVOLVING FLAGAL PARASITES
MX2011010920A (en) Biomarker for monitoring patients.
MX2011010061A (en) Biomarker for monitoring patients.